Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Shinohara, M.; Ybanez, M.D.; Win, S.; Than, T.A.; Jain, S.; Gaarde, W.A.; Han, D.; Kaplowitz, N.
    Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1 (2010), J. Biol. Chem., 285, 8244-8255.
    View publication on PubMedView publication on EuropePMC

Application

EC Number Application Comment Organism
6.3.2.2 medicine activation of glycogen synthase kinase 3beta is a key mediator of the initial phase of acetaminophen-induced liver injury through modulating GCL and Mcl-1 degradation, as well as JNK activation in liver. The silencing of glycogen synthase kinase 3beta decreases the loss of hepatic GCL, and promotes greater GSH recovery in liver following acetaminophen treatment Mus musculus

Inhibitors

EC Number Inhibitors Comment Organism Structure
6.3.2.2 acetaminophen treatment promotes the loss of glutamate cysteine ligase in liver. Activation of glycogen synthase kinase 3beta is a key mediator of the initial phase of acetaminophen-induced liver injury through modulating GCL and Mcl-1 degradation, as well as JNK activation in liver. The silencing of glycogen synthase kinase 3beta decreases the loss of hepatic GCL, and promotes greater GSH recovery in liver following acetaminophen treatment Mus musculus

Organism

EC Number Organism UniProt Comment Textmining
6.3.2.2 Mus musculus
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
6.3.2.2 hepatocyte
-
 Mus musculus
-
6.3.2.2 liver
-
 Mus musculus
-
6.3.2.2 primary cell
-
 Mus musculus
-